Biocross is pleased to present at the 2016 Alzheimer’s Association International Conference (AAIC) in Toronto its work on the influence of APOE ε4 carrier status on the metabolomic profile of AD patients versus cognitively normal controls. The AAIC is the world’s largest forum for the dementia research community. Researchers, clinicians, care providers, and students from over 70 countries gather at AAIC to network and discuss the results, theories, and discoveries arising from the latest dementia research.
APOE ε4 is arguably the most important genetic risk factor for late-onset AD. As a major apolipoprotein its role in lipid metabolism is clear. Moreover, APOE ε4 carrier status has been shown to be associated with a consistent transcriptomic shift in the brain that resembles the late-onset AD profile. However, APOE genotype does not alter the diagnostic accuracy of cerebrospinal fluid biomarkers for AD. In this study, Biocross researchers investigated whether APOE ε4 carrier status modifies the metabolomics profile of AD patients relative to that of cognitively normal controls.
The results revealed that APOE ε4 stratification of AD patients defines two distinct sets of metabolomics markers related to dysregulation of lipid (APOE ε4 carriers) or mitochondrial (APOE ε4 non-carriers) metabolism. Stratification according to APOE ε4 status may help to identify specific subsets of metabolomics markers that enable more accurate risk prediction and disease diagnosis.
Presentation Details
Title: APOE ε4 stratification of Alzheimer’s disease patients defines two distinct sets of plasma metabolomics marker related to lipid and mitochondrial metabolism dysfunction.
Date/Time: 12 a.m. EST, Tuesday, July 26, 2016.
Location: Room Hall D/E (P3-172), Toronto Convention Centre, Toronto, Canada
